Lupin Pharmaceuticals Inc. has voluntarily recalled 16,056 bottles of Rifampin Capsules USP (300 mg), an antibiotic used to treat tuberculosis and other infections. The recall was issued after the medication failed testing for impurities and degradation during a long-term stability study. No incidents or injuries have been reported to date in connection with this issue.
The failure to meet impurity and degradation specifications means the medication may contain chemical substances that do not meet safety and quality standards, which could potentially impact the drug's effectiveness or cause adverse health effects.
You have 2 options:
Recall #: D-0100-2023; Manufactured by Lupin Limited in India for Lupin Pharmaceuticals Baltimore, Maryland.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.